Drugs / Becocalcidiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00373516 | Sep 2004 → Mar 2005 | psoriasis | QuatRx Pharmaceuticals Company | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Becocalcidiol | “BACKGROUND: Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.” PMID 17596167 ↗ Jun 2007 |
| Known as | 2MBisP | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104955 ↗ |
| Known as | DP-006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104955 ↗ |
| Known as | QRX 101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104955 ↗ |
| Action | Activate | “Vitamin D receptor agonist” CHEMBL2104955 ↗ |
| Modality | Small molecule | — CHEMBL2104955 ↗ |
| Route | Topical | “comparing topical application of placebo, becocalcidiol 75 microg g(-1) once daily (low dose) or becocalcidiol twice daily (high dose) for 8 weeks” PMID 17596167 ↗ Jun 2007 |
| Target | VDR | “Vitamin D receptor agonist” CHEMBL2104955 ↗ |